Ovarian cancer (OVCA) inevitably acquires resistance to platinum chemotherapy and PARP
inhibitors (PARPi). We show that acquisition of PARPi-resistance is accompanied by …

The gene encoding ARID1A, a chromatin remodeler, shows one of the highest mutation rates
across many cancer types. Notably, ARID1A is mutated in over 50% of ovarian clear cell …

In senescent cells, specialized domains of transcriptionally silent senescence-associated
heterochromatic foci (SAHF), containing heterochromatin proteins such as HP1, are thought to …

PARP inhibition is known to be an effective clinical strategy in BRCA mutant cancers, but PARP
inhibition has not been applied to BRCA-proficient tumors. Here, we show the synergy of …

Cancer is a disease of ageing. Clinically, aged cancer patients tend to have a poorer prognosis
than young. This may be due to accumulated cellular damage, decreases in adaptive …

Restoration of anti-tumor immunity by blocking PD-L1 signaling through the use of antibodies
has proven to be beneficial in cancer therapy. Here, we show that BET bromodomain …

ARID1A, encoding a subunit of the SWI/SNF chromatin-remodelling complex, is the most
frequently mutated epigenetic regulator across all human cancers. ARID1A and TP53 …

Senescence is characterized by an irreversible cell proliferation arrest. Specialized domains
of facultative heterochromatin, called senescence-associated heterochromatin foci (SAHF), …

The dominant TLR5 R392X polymorphism abrogates flagellin responses in >7% of humans.
We report that TLR5-dependent commensal bacteria drive malignant progression at …

Oncogene-induced senescence is characterized by a stable cell growth arrest, thus
providing a tumor suppression mechanism. However, the underlying mechanisms for this …